Item is in stockHurry! Low InventoryItem is out of stock. Item is unavailable
Proper Handling

Product Specifications: 10mg Lyophilized Powder (>98% purity) in 4ml vial.*Requires reconstitution with solvent such as Bacteriostatic Water. Speak to a qualified healthcare professional if you are considering peptide therapy.

Need to speak with a clinician?

Schedule a telehealth consultation with a practitioner specialized in peptide therapy, who will review your medical history and determine the best plan for you.

Retatrutide is an investigational treatment for obesity that is a triple hormone receptor agonist. Retatrutide is a gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist.

Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones:

  • GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. It stimulates the beta-cells in the pancreas to secrete insulin.
  • GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.
  • Glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps maintain adequate plasma glucose concentrations.

The drug has been nicknamed 'triple G' because it is an agonist of all three receptors.

CAS Number 2381089-83-2

PubChem CID 474492335

Molecular Weight 4845.44 g/mol

Molecular Formula C223H343F3N46O70

Synonyms LY-3437943, NOP2Y096GV

GCGR agonists(Glucagon receptor agonists),GIPR agonists(Gastric inhibitory polypeptide receptor agonists),GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Storage (Lyophilized) At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years

  1. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X
  2. Urva S, O’Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. doi: 10.1111/dom.15167
  3. Sinha B, Ghosal S, Mukhopadhyay S, et al. Glucagon-related advancements in diabetes therapy. J Diabetol. 2023;14:S16-S18. doi: 10.4103/jod.jod_96_23

Buy It With

BPC-157 / TB-500 Blend


 TB-500 Blend

Buy It With

Bacteriostatic Water


Bacteriostatic Water

Frequently Asked Questions


Free Shipping

on all orders over $200 delivered straight to your doorstep

Easy Telehealth

Ongoing care available, 100% online at your convenience

Quality First

All peptides are clinical grade and undergoes third-party testing

Proactive Care

Your journey, your way. We are here to support your health goals.


Your body, your journey .

Embarking on the journey to better health involves embracing holistic well-being through consultative care. It's not just about staying clear of sickness; it's about finding balance in body and mind.